TriSalus Life Sciences, Inc. (TLSI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TLSI SEC filings page.
TriSalus Life Sciences, Inc. (TLSI) reported $45.1M in revenue over the twelve months to Jun 30, 2026, up 25.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but TriSalus still funds an operating loss through financing while its balance sheet remains liability-heavy.
By FY2025, revenue reached$45.2M while operating margin improved to-59.7% from the earlier loss structure. Operating cash flow of-$18.0M was close to free cash flow of-$18.9M , showing that the shortfall is primarily operating rather than caused by heavy capital spending.
Gross margin stayed near 85% through the latest period, so the improved operating result was not driven by expanding product-level margins. Instead, R&D fell from
FY2025 liabilities of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of TriSalus Life Sciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
TriSalus Life Sciences, Inc. held $20.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $18.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and TriSalus Life Sciences, Inc. scores 36/100 among other emerging companies.
TriSalus Life Sciences, Inc. had 61M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and TriSalus Life Sciences, Inc. scores 19/100 among other emerging companies.
TriSalus Life Sciences, Inc. spent $15.0M on research and development in fiscal year 2025, which was 20.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and TriSalus Life Sciences, Inc. scores 52/100 among other emerging companies.
TriSalus Life Sciences, Inc. reported revenue of $45.2M in fiscal year 2025, against $29.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and TriSalus Life Sciences, Inc. scores 80/100 among other emerging companies.
TriSalus Life Sciences, Inc.'s operations used $18.0M of cash in fiscal year 2025, against $40.8M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and TriSalus Life Sciences, Inc. scores 77/100 among other emerging companies.
TriSalus Life Sciences, Inc.'s cash, cash equivalents and investments came to $20.4M at the end of fiscal year 2025, against $69.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and TriSalus Life Sciences, Inc. scores 33/100 among other emerging companies.
TriSalus Life Sciences, Inc. scores -11.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($254.9M) relative to total liabilities ($69.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
TriSalus Life Sciences, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
TriSalus Life Sciences, Inc. reported a net loss of $39.2M while operations used $18.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
TriSalus Life Sciences, Inc. reported an operating loss of $26.9M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
TriSalus Life Sciences, Inc. generated $11.4M in revenue in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 28.2%.
TriSalus Life Sciences, Inc.'s EBITDA was -$9.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.0% from the same quarter a year earlier. Against the prior quarter it is down 16.9%.
TriSalus Life Sciences, Inc. reported -$9.2M in net income in Q2 2026. This represents a decrease of 10.8% from the same quarter a year earlier. Against the prior quarter it is down 696.9%.
TriSalus Life Sciences, Inc. earned -$0.16 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 633.3%.
Cash & Balance Sheet
TriSalus Life Sciences, Inc. recorded an outflow of $10.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 37.7% from the same quarter a year earlier. Against the prior quarter it is down 54.2%.
TriSalus Life Sciences, Inc. held $46.3M in cash against $33.1M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
TriSalus Life Sciences, Inc.'s gross margin was 86.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
TriSalus Life Sciences, Inc.'s operating margin was -86.0% in Q2 2026, reflecting core business profitability. This is down 20.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.5 percentage points.
TriSalus Life Sciences, Inc.'s net profit margin was -80.5% in Q2 2026, showing the share of revenue converted to profit. This is down 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 97.8 percentage points.
TriSalus Life Sciences, Inc.'s ROE was -140.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 152.3 percentage points.
Capital Allocation
TriSalus Life Sciences, Inc. invested $3.1M in research and development in Q2 2026. This represents a decrease of 14.5% from the same quarter a year earlier. Against the prior quarter it is down 2.5%.
TriSalus Life Sciences, Inc. invested $82K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 11.8% from the same quarter a year earlier. Against the prior quarter it is down 41.8%.
Not reported for Q2 2026.
TLSI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M+1.7% | $8.9M-2.9% | $13.2M+59.8% | $11.6M+57.4% | $11.2M+52.3% | $9.2M+42.0% | $8.3M+44.4% | $7.3M+41.5% |
| Cost of Revenue | $1.5M-16.3% | $1.2M-17.7% | $1.8M+44.9% | $1.9M+89.8% | $1.8M+97.6% | $1.5M+54.0% | $1.2M+108.9% | $1.0M+70.5% |
| Gross Profit | $9.9M+5.2% | $7.7M0.0% | $11.4M+62.4% | $9.7M+52.2% | $9.4M+45.9% | $7.7M+39.8% | $7.0M+37.1% | $6.3M+37.8% |
| R&D Expenses | $3.1M-14.5% | $3.2M+6.5% | $3.1M+4.7% | $5.2M+22.7% | $3.7M-21.3% | $3.0M-48.3% | $3.0M-62.1% | $4.2M-55.6% |
| SG&A Expenses | $5.2M-12.7% | $5.5M+3.9% | $3.6M-21.8% | $6.7M+40.9% | $5.9M+49.4% | $5.2M+13.4% | $4.7M-22.9% | $4.7M-47.6% |
| Operating Income | -$9.8M-33.8% | -$8.4M-14.8% | -$3.3M+56.8% | -$9.0M-3.1% | -$7.3M+10.3% | -$7.3M+37.2% | -$7.6M+47.0% | -$8.7M+53.1% |
| EBITDA | -$9.7M-35.0% | -$8.3M-15.6% | -$3.1M+57.4% | -$8.9M-3.4% | -$7.2M+10.2% | -$7.2M+37.7% | -$7.4M+47.6% | -$8.6M+53.6% |
| Interest Expense | $1.5M+4.7% | $1.4M+18.8% | $1.5M+36.0% | $1.5M+27.8% | $1.4M+62.3% | $1.2M+40200.0% | $1.1M+35500.0% | $1.1M+28450.0% |
| Income Tax | $4K+233.3% | $4K-20.0% | $0+100.0% | $5K+266.7% | -$3K-142.9% | $5K+66.7% | -$1K-200.0% | -$3K |
| Net Income | -$9.2M-10.8% | $1.5M+114.8% | -$9.8M+3.5% | -$10.8M-350.6% | -$8.3M-91.3% | -$10.4M+21.4% | -$10.1M+71.6% | -$2.4M-68.4% |
| EPS (Basic) | -$0.16+40.7% | $0.03+107.7% | -$0.12+70.0% | -$0.96-700.0% | -$0.27-28.6% | -$0.39+35.0% | -$0.40+61.9% | -$0.12+14.3% |
| EPS (Diluted) | -$0.16 | $0.03 | -$0.12 | -$0.96 | -$0.27-28.6% | -$0.39+35.0% | -$0.40+61.9% | -$0.12 |
| Diluted Shares (Avg) | 58M | 52M | N/A | 43M | 33M+37.6% | 29M+22.3% | N/A | 27M |
TLSI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $62.4M+51.1% | $71.0M+148.0% | $35.3M+47.4% | $36.5M+32.7% | $41.3M+27.4% | $28.6M+60.0% | $24.0M-2.5% | $27.5M-18.1% |
| Current Assets | $59.7M+56.9% | $68.1M+171.5% | $32.2M+56.0% | $33.3M+40.0% | $38.1M+36.3% | $25.1M+90.3% | $20.7M-0.9% | $23.8M-18.0% |
| Cash & Equivalents | $46.3M+74.7% | $56.6M+335.0% | $20.4M+139.8% | $22.7M+101.0% | $26.5M+60.7% | $13.0M+227.5% | $8.5M-27.6% | $11.3M-47.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $4.2M+10.5% | $3.8M-9.2% | $3.1M-24.0% | $3.3M-18.1% | $3.8M+10.6% | $4.2M+42.9% | $4.0M+59.1% | $4.0M+145.5% |
| Accounts Receivable | $6.5M+15.9% | $5.2M-4.4% | $6.6M+28.9% | $5.0M+1.8% | $5.6M+18.4% | $5.5M+27.5% | $5.1M+43.1% | $4.9M+60.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $55.9M-8.0% | $58.2M-7.7% | $69.2M+38.8% | $63.2M+31.9% | $60.7M+7.4% | $63.0M+19.3% | $49.9M-3.5% | $47.9M+91.1% |
| Current Liabilities | $11.2M+19.8% | $11.8M+0.3% | $11.5M+12.4% | $10.9M+10.0% | $9.3M-22.3% | $11.8M-18.3% | $10.2M-30.4% | $9.9M+6.6% |
| Non-Current Liabilities | $44.7M-13.0% | $46.4M-9.5% | $57.7M+45.6% | $52.3M+37.6% | $51.4M+15.3% | $51.2M+33.4% | $39.6M+7.2% | $38.0M+141.0% |
| Long-Term Debt | $33.1M+2.5% | $33.1M+4.4% | $33.0M+49.6% | $32.8M+51.1% | $32.3M+51.6% | $31.7M | $22.1M | $21.7M |
| Total Equity | $6.5M+133.7% | $12.8M+137.3% | -$33.9M-30.8% | -$26.7M-30.8% | -$19.4M+23.1% | -$34.4M+4.6% | -$25.9M+4.3% | -$20.4M-346.4% |
| Retained Earnings | -$338.2M-13.4% | -$329.0M-13.5% | -$330.6M-18.3% | -$321.0M-19.1% | -$298.2M-12.1% | -$289.9M-10.8% | -$279.5M-12.0% | -$269.4M-26.6% |
Not reported in any period shown, so not listed: Goodwill.
TLSI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.1M-38.4% | -$6.5M-44.0% | -$2.5M+56.5% | -$3.7M+65.8% | -$7.3M+45.5% | -$4.5M+58.6% | -$5.7M+37.8% | -$10.8M+49.9% |
| Depreciation & Amortization | $136K-17.6% | $135K-21.5% | $126K-34.7% | $163K-10.4% | $165K-14.9% | $172K-1.7% | $193K-0.5% | $182K+16.7% |
| Stock-Based Compensation | N/A | $2.5M+52.6% | N/A | N/A | N/A | $1.6M+49.2% | N/A | N/A |
| Capital Expenditures | $82K-11.8% | $141K-81.3% | $41K-18.0% | $216K+27.8% | -$93K+55.0% | $754K+1042.4% | $50K-86.6% | $169K-5.1% |
| Free Cash Flow | -$10.2M-37.7% | -$6.6M-26.0% | -$2.5M+56.1% | -$3.9M+64.4% | -$7.4M+45.0% | -$5.3M+52.0% | -$5.8M+39.7% | -$11.0M+49.6% |
| Investing Cash Flow | -$82K-188.2% | -$141K+80.3% | -$41K+18.0% | -$176K-4.1% | $93K+255.0% | -$714K-981.8% | -$50K+86.6% | -$169K+84.8% |
| Financing Cash Flow | -$54K-100.3% | $42.4M+337.5% | $277K-90.7% | $82K-98.6% | $20.7M-20.3% | $9.7M+209.9% | $3.0M+6862.8% | $5.8M-85.5% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TLSI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.8%+2.8pp | 86.2%+2.5pp | 86.7%+1.4pp | 83.5%-2.8pp | 83.9%-3.7pp | 83.7%-1.3pp | 85.3%-4.5pp | 86.3%-2.3pp |
| Operating Margin | -86.0%-20.6pp | -94.5%-14.6pp | -24.8%+67.0pp | -77.9% | -65.4% | -80.0% | -91.8% | -118.9% |
| Net Margin | -80.5%-6.6pp | 17.3% | -73.9% | -93.5%-60.8pp | -73.9%-15.1pp | -113.2% | -122.4% | -32.6%-5.2pp |
| Return on Equity | -140.3% | 12.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -14.7%+5.3pp | 2.2%+38.4pp | -27.6%+14.6pp | -29.6%-20.9pp | -20.1%-6.7pp | -36.2%+37.6pp | -42.2%+102.7pp | -8.7%-4.5pp |
| Current Ratio | 5.35+1.3x | 5.78+3.6x | 2.80+0.8x | 3.05+0.7x | 4.08+1.8x | 2.14+1.2x | 2.02+0.6x | 2.40-0.7x |
| Debt-to-Equity | 5.05 | 2.58 | N/A | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.18-0.1x | 0.13-0.2x | 0.370.0x | 0.320.0x | 0.270.0x | 0.320.0x | 0.34+0.1x | 0.27+0.1x |
| FCF Margin | -89.5%-23.4pp | -74.4%-17.1pp | -19.1%+50.6pp | -33.9% | -66.1% | -57.3% | -69.7% | -149.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$33.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. TLSI | FY2025 | $45.2M | -$39.2M | -86.9% | $254.9M | 50/100 |
| Perspective Therapeutics, Inc. CATX | FY2025 | N/A | -$103.1M | N/A | $303.6M | — |
| Cerus Corp CERS | FY2025 | $233.8M | -$15.6M | -6.7% | $463.5M | 37/100 |
| Quantum-Si Incorporated QSI | FY2025 | $2.4M | -$101.3M | N/A | $334.9M | 58/100 |
| Monogram Technologies Inc. MGRM | FY2024 | N/A | -$16.3M | N/A | $243.8M | — |
| Inogen Inc INGN | FY2025 | $348.7M | $22.7M | 6.5% | $164.0M | 42/100 |
Where TriSalus Life Sciences, Inc. Ranks
Frequently Asked Questions
What is TriSalus Life Sciences, Inc.'s annual revenue?
TriSalus Life Sciences, Inc. (TLSI) reported $45.2M in total revenue for fiscal year 2025. This represents a 53.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is TriSalus Life Sciences, Inc.'s revenue growing?
TriSalus Life Sciences, Inc. (TLSI) revenue grew by 53.4% year-over-year, from $29.4M to $45.2M in fiscal year 2025.
Is TriSalus Life Sciences, Inc. profitable?
No, TriSalus Life Sciences, Inc. (TLSI) reported a net income of -$39.2M in fiscal year 2025, with a net profit margin of -86.9%.
What is TriSalus Life Sciences, Inc.'s EBITDA?
TriSalus Life Sciences, Inc. (TLSI) had EBITDA of -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does TriSalus Life Sciences, Inc. have?
As of fiscal year 2025, TriSalus Life Sciences, Inc. (TLSI) had $20.4M in cash and equivalents against $33.0M in long-term debt.
What is TriSalus Life Sciences, Inc.'s gross margin?
TriSalus Life Sciences, Inc. (TLSI) had a gross margin of 84.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is TriSalus Life Sciences, Inc.'s operating margin?
TriSalus Life Sciences, Inc. (TLSI) had an operating margin of -59.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is TriSalus Life Sciences, Inc.'s net profit margin?
TriSalus Life Sciences, Inc. (TLSI) had a net profit margin of -86.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is TriSalus Life Sciences, Inc.'s free cash flow?
TriSalus Life Sciences, Inc. (TLSI) recorded an outflow of $18.9M in free cash flow during fiscal year 2025. This represents a 54.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TriSalus Life Sciences, Inc.'s operating cash flow?
TriSalus Life Sciences, Inc. (TLSI) recorded an outflow of $18.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are TriSalus Life Sciences, Inc.'s total assets?
TriSalus Life Sciences, Inc. (TLSI) had $35.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TriSalus Life Sciences, Inc.'s capital expenditures?
TriSalus Life Sciences, Inc. (TLSI) invested $918K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TriSalus Life Sciences, Inc. spend on research and development?
TriSalus Life Sciences, Inc. (TLSI) invested $15.0M in research and development during fiscal year 2025.
What is TriSalus Life Sciences, Inc.'s current ratio?
TriSalus Life Sciences, Inc. (TLSI) had a current ratio of 2.80 as of fiscal year 2025, which is generally considered healthy.
What is TriSalus Life Sciences, Inc.'s return on assets (ROA)?
TriSalus Life Sciences, Inc. (TLSI) had a return on assets of -111.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TriSalus Life Sciences, Inc.'s P/E ratio?
TriSalus Life Sciences, Inc. (TLSI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $254.9M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is TriSalus Life Sciences, Inc.'s price-to-sales ratio?
TriSalus Life Sciences, Inc. (TLSI) trades at 5.7x sales, its market capitalization divided by revenue of $45.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $254.9M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does TriSalus Life Sciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, TriSalus Life Sciences, Inc. (TLSI) held $20.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $18.0M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is TriSalus Life Sciences, Inc.'s debt-to-equity ratio negative or not reported?
TriSalus Life Sciences, Inc. (TLSI) has negative shareholder equity of -$33.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is TriSalus Life Sciences, Inc.'s Altman Z-Score?
TriSalus Life Sciences, Inc. (TLSI) has an Altman Z-Score of -11.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is TriSalus Life Sciences, Inc.'s Piotroski F-Score?
TriSalus Life Sciences, Inc. (TLSI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TriSalus Life Sciences, Inc.'s earnings high quality?
TriSalus Life Sciences, Inc. (TLSI) reported a net loss of $39.2M while operations used $18.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can TriSalus Life Sciences, Inc. cover its interest payments?
TriSalus Life Sciences, Inc. (TLSI) reported an operating loss of $26.9M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is TriSalus Life Sciences, Inc.?
TriSalus Life Sciences, Inc. (TLSI) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.